CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5259.07M
Enterprise Value 3556.09M
Trailing P/E N/A
Forward P/E 1-0.81
PEG Ratio (5 yr expected) 1-0.02
Price/Sales (ttm)2.17
Price/Book (mrq)N/A
Enterprise Value/Revenue 34.66
Enterprise Value/EBITDA 6-1.55

Trading Information

Stock Price History

Beta (3Y Monthly) 2.22
52-Week Change 3-85.08%
S&P500 52-Week Change 32.99%
52 Week High 334.6300
52 Week Low 34.7200
50-Day Moving Average 35.8756
200-Day Moving Average 315.1149

Share Statistics

Avg Vol (3 month) 33.49M
Avg Vol (10 day) 35.11M
Shares Outstanding 554.66M
Float 43.02M
% Held by Insiders 13.00%
% Held by Institutions 1103.65%
Shares Short (Aug 15, 2019) 417.47M
Short Ratio (Aug 15, 2019) 44.12
Short % of Float (Aug 15, 2019) 434.46%
Short % of Shares Outstanding (Aug 15, 2019) 431.97%
Shares Short (prior month Jul 15, 2019) 411.19M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-306.02%

Management Effectiveness

Return on Assets (ttm)-27.57%
Return on Equity (ttm)-280.47%

Income Statement

Revenue (ttm)119.2M
Revenue Per Share (ttm)2.26
Quarterly Revenue Growth (yoy)38.80%
Gross Profit (ttm)75.94M
EBITDA -358.06M
Net Income Avi to Common (ttm)-395.97M
Diluted EPS (ttm)-7.4950
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)315.91M
Total Cash Per Share (mrq)5.78
Total Debt (mrq)612.93M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.57
Book Value Per Share (mrq)-0.56

Cash Flow Statement

Operating Cash Flow (ttm)-351.64M
Levered Free Cash Flow (ttm)-152.23M